Latest from University of Chicago Medicine Comprehensive Cancer Center

Thomas F. Gajewski, MD, PhD, discusses how the combination of PD-1 and IDO inhibitors could change the standard of care for patients with melanoma, and highlights other emerging targets on the horizon.
Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses biomarkers for immunotherapy in head and neck cancer.
Jason J. Luke, MD, discusses adjuvant therapy for patients with melanoma, as well as the future of targeted agents and immunotherapy.
Christopher R. Shea, MD, expresses the importance of expanding melanoma knowledge to more specialists as well as the advancements in pathology over the last several years.
Jason J. Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses some of the ongoing adjuvant therapies in development for patients with melanoma. Luke shared this insight during the 2017 OncLive State of the Science Summit on Melanoma and Immuno-Oncology.
Stacie Levine, MD, associate professor of Medicine, director, Geriatrics and Hospice and Palliative Medicine Fellowship Program, University of Chicago Medicine, discusses the benefits of palliative care for patients with nonsmall cell lung cancer (NSCLC).
Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses ongoing clinical trials in the field of head and neck cancer.
Everett Vokes, MD, John E. Ultmann professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses different settings of patients with head and neck cancer.
Publication Bottom Border
Border Publication